1xbet 신청 Pharmaceutical Co., Ltd.

Otsuka Pharmaceutical Co., Ltd.'s (Otsuka) wholly owned subsidiary Astex Pharmaceuticals in Cambridge, U.K., (Astex), announced that it will receive a milestone payment from AstraZeneca PLC (AstaZeneca) on first commercial sale of 1xbet 신청 drug Truqap and receive royalties from AstraZeneca on future sales following U.S. FDA approval of Truqap™ plus Faslodex^®as a treatment for adult patients with HR-positive, HER2-negative, locally advanced or metastatic breast cancer with one or more biomarker alterations (PIK3CA, AKT1 or PTEN). Eligible patients will have progressed on at least one endocrine-based regimen in 1xbet 신청 metastatic setting or experienced recurrence on or within 12 months of completing adjuvant 1xbet 신청rapy.

Truqap is a first-in-class oral targeted inhibitor of 1xbet 신청 cancer-driving protein AKT, also known as PKB. Truqap was discovered by AstraZeneca following an earlier drug discovery research collaboration between Astex, 1xbet 신청 Institute of Cancer Research, London, and Cancer Research Technology (now Cancer Research Horizons) that was signed in 2003. As part of that earlier foundational research, Astex and 1xbet 신청 Institute of Cancer Research used 1xbet 신청 3D X-ray crystal structure of 1xbet 신청 AKT protein target to identify small molecule modulators of AKT activity using an approach known as fragment-based drug discovery.